Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)
Main finding · AKI by SGLT2i use, stratified by CKDResult — go to the resultOdds ratio 0.70 95% CI 0.42–0.91Authors' conclusion
In diabetic patients with CKD undergoing TAVI, SGLT2i therapy was associated with a lower occurrence of AKI compared to those not treated with SGLT2i, suggesting a potential nephroprotective effect in this high-risk population.
Study context
- Population
- Consecutive T2D patients with severe aortic stenosis undergoing TAVI, 2021–2024; median age 81 [77–84] years, 60.1% males
- Participants
- 514 patients
- Exposure
- SGLT2i vs no-SGLT2i users, stratified by chronic kidney disease (CKD)
- Outcome
- AKI per VARC-3 criteria
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
AKI by SGLT2i use, stratified by CKD
Odds ratio
0.70
95% CI 0.42–0.91
P = 0.014
By group
SGLT2i (CKD)vs No-SGLT2i (CKD)
OR 0.70 (95% CI 0.42–0.91); P = 0.014
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Serum creatinine post-TAVI and at discharge (CKD)No-SGLT2i (CKD) vs SGLT2i (CKD) · significant increase with no-SGLT2i | P = 0.001 after TAVI |
| Serum creatinine post-TAVI and at discharge (CKD)No-SGLT2i (CKD) vs SGLT2i (CKD) · significant increase with no-SGLT2i | P < 0.001 at hospital discharge |
MACE during follow-up, acute kidney injury (AKI) vs no AKI
- Higher MACE incidence in patients with AKI, regardless of CKD (p < 0.025 for both groups)
Original publication
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Cardiovasc Diabetol. Published 21 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →